Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NOV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NOV and 80,000+ other tickers.
See exactly how NOV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NOV and 80,000+ other tickers.
NOV Inc. is a global leader in designing, manufacturing, and marketing essential systems, components, and products for the oil and gas drilling and production industries, as well as for industrial and renewable energy sectors worldwide. The company's operations are divided into three core segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. The Wellbore Technologies segment provides a range of offerings including solids control and waste management equipment, portable power generation units, drill and wired pipes, advanced drilling optimization and…
NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
NOV shares rise 32% over the past six months as offshore demand, backlog growth and efficiency gains boost prospects despite tariffs and risks.